In early 2025, Stablepharma Ltd was awarded €2.5 million in grant funding through the EIC Accelerator to advance its StablevaX™ technology, an innovation set to transform vaccine distribution by removing the need for cold‑chain logistics.
FI Group UK played a pivotal role in reviewing and strengthening the company’s final submission. Working closely with Stablepharma’s executive team, FI Group helped refine the technical narrative, align financials with key clinical milestones, and enhance the overall credibility and clarity of the application. The award made Stablepharma one of just five UK companies selected in a highly competitive round of over 1,200 applicants.
This success highlights how expert grant consultancy can significantly improve outcomes for high-potential applicants seeking funding under Horizon Europe’s most competitive instruments.